tiprankstipranks

Theriva Biologics achieves target patient enrollment in VIRAGE Phase 2b trial

Theriva Biologics has achieved their target patient enrollment in the VIRAGE Phase 2b clinical trial evaluating the Company’s lead product candidate VCN-01 plus standard-of-care chemotherapy as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma. VCN-01 is a systemically-administered, tumor selective, stroma-degrading oncolytic adenovirus that has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration for the treatment of PDAC.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue